Instanyl® Non-Interventional Study (INIS)

Takeda

Status: Completed

Conditions: Breakthrough Cancer Pain

Study type: Observational

Funder types: Industry

Identifiers

NCT01045603

U1111-1136-4251 (Registry Identifier)

FT-1301-034-SP

Details and patient eligibility

About

The aim of this study is to describe the use of Instanyl® (Intranasal fentanyl spray) in the treatment of breakthrough pain (BTP) in cancer patients by success of dose titration and distribution of dose strength. Data will be collected at three different time points over a 3 month period.

Enrollment: 309 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Adult cancer patients suffering from BTP
• Instanyl should be prescribed in accordance with the Summary of Product Characteristics (SPC) and none of the stated contradictions applies
• The decision to prescribe should be made independently of the study
• All patients must provide signed Informed Consent prior to inclusion